A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Items 301–400 of 638
Pharmacotherapy for obsessive—compulsive disorder
Fineberg, N. A., & Brown, A. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.109.007237 · Cited by 15
Sina, M., Ahmadiani, A., Asadi, S., & Shams, J. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s163946 · Cited by 14
“25% reduction in Y-BOCS scores after treatment with fluvoxamine and group B (nonresponders) comprised patients who exhibited ,25% reduction in Y-BOCS scores.(43,44) We also included another group (refractory patients) consisting of patients who experienced various SSRI trials during their illness period, but did not r…”
ResultPrescribing antipsychotics for children and adolescents
James, A. C. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005652 · Cited by 14
Psychotherapeutische und medikamentöse Behandlung der kindlichen Zwangsstörung
Vloet, T. D., Simons, M., & Herpertz‐Dahlmann, B. (2011) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000147 · Cited by 15
Löchner, C., Chamberlain, S. R., Kidd, M., Fineberg, N. A., & Stein, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4172-y · Cited by 14
Lv, Q., Wang, Z., Zhang, C., Fan, Q., Zhao, Q., Zeljic, K., Sun, B., Xiao, Z., & Wang, Z. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.021 · Cited by 13
“…therapeutic mechanisms of pharmacotherapy remain essentially unclear while as many as half of patients diagnosed with OCD fail to the CC BY license (http://creativecommons.org/licenses/by/4.0/). respond adequately to serotonergic-based drugs (Bloch et al., 2006, 2010; Hirschtritt et al., 2017).”
BackgroundInfluentialGarabadu, D., & Kumar, V. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000468 · Cited by 14
Effectiveness of aripiprazole in treating obsessive compulsive symptoms
Yang, K., Su, T., & Chou, Y.-H. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.10.009 · Cited by 17
Karadağ, F., Oğuzhanoğlu, N. K., Yüksel, D., Kıraç, S., Cura, Ç., Özdel, O. İ., & Ateşçi, F. Ç. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.07.005 · Cited by 16
“Although selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice in OCD patients, as many as 40–60% of patients may not respond or may have only a partial response to these medications (Bloch et al., 2006; Pallanti and Quercioli, 2006).”
BackgroundKatzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2023) · doi:10.32920/14638581 · Cited by 13
Pharmacotherapy for Children and Adolescents with Anxiety Disorders
Vitiello, B., & WASLICK, B. D. (2010) · Psychiatric Annals · doi:10.3928/00485713-20100330-09 · Cited by 12
Current and emerging pharmacotherapeutic strategies for Tourette syndrome
Cavanna, A. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2107902 · Cited by 14
“times more likely to respond to the dual pharmacotherapy, compared to those without tics [46].”
BackgroundAnatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain
Ishii, T., Kimura, Y., Ichise, M., Takahata, K., Kitamura, S., Moriguchi, S., Kubota, M., Zhang, M.-R., Yamada, M., Higuchi, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189318 · Cited by 15
Asaoka, N., Ibi, M., Hatakama, H., Nagaoka, K., Iwata, K., Matsumoto, M., Katsuyama, M., Kaneko, S., & Yabe‐Nishimura, C. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2121-20.2021 · Cited by 12
“Clinical imaging studies revealed a reduction in D2 receptor binding availability, which reflects low membrane expression of D2 receptor and/or increased dopamine release, in the striatum of patients with OCD and substance use disorder (Denys et al., 2004; Fehr et al., 2008; Lee et al., 2009).”
BackgroundInfluentialChohan, M. O., Kopelman, J. M., Yueh, H., Fazlali, Z., Greene, N., Harris, A. Z., Balsam, P. D., Leonardo, E. D., Kramer, E. R., Veenstra-VanderWeele, J. M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01424-3 · Cited by 14
“We focused on EAAT3 activity in dopaminergic neurons because of the well-established importance of dopamine in repetitive behaviors [37, 43, 47, 48, 74], and our previous work in EAAT3 knockout mice [75] that suggested involvement of midbrain EAAT3 expression in pharmacologically-induced-repetitive behaviors.”
ResultObsessive-Compulsive Syndromes in Schizophrenia: A Case for Polypharmacy?
Schirmbeck, F. N., & Zink, M. (2012) · Springer eBooks · doi:10.1007/978-94-007-5799-8_12 · Cited by 14
Higuma, H., Kanehisa, M., Maruyama, Y., Ishitobi, Y., Tanaka, Y., Tsuru, J., Hanada, H., Kodama, K., Isogawa, K., & Akiyoshi, J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.551667 · Cited by 13
“Responsiveness was defi ned as a decrease of at least 25% in Y-BOCS score after aripiprazole/SSRI co-treatment (Bloch et al. 2006).”
MethodPittenger, C., Bloch, M. H., Wegner, R., Teitelbaum, C., Krystal, J. H., & Coric, V. (2006) · Primary psychiatry · Cited by 15
Self-citationPersonality measures after gamma ventral capsulotomy in intractable OCD
Paiva, R. R., Batistuzzo, M. C., McLaughlin, N. C. R., Canteras, M. M., de Mathis, M. E., Requena, G. D. L., Shavitt, R. G., Greenberg, B. D., Noren, G. C., Rasmussen, S. A., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.023 · Cited by 15
“Standard treatments for OCD are serotonin reuptake inhibitors (SRIs) medications and cognitive-behavioral therapy (CBT) (BelottoSilva et al., 2012; Bloch et al., 2006; Castle et al., 2015).”
BackgroundReview: Intravenous anti-obsessive agents: a review
Ravindran, L., Jung, S., & Ravindran, A. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096508 · Cited by 15
Obsessive-compulsive disorder – A state-of-the-art review
Endres, D., Schiele, M. A., von Zedtwitz, K., Dressle, R. J., Maier, A., Hohagen, F., Baldermann, J. C., Coenen, V. A., Jelinek, L., Domschke, K., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106320 · Cited by 11
Segalàs, C., Cernadas, E., Puialto, M., Fernández-Delgado, M., Arrojo, M., Bertolín, S., Real, E., Menchón, J. M., Carracedo, Á., Tubío-Fungueiriño, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.157 · Cited by 11
Umehara, H., Numata, S., Tajima, A., Kinoshita, M., Nakaaki, S., Imoto, I., Sumitani, S., & Ohmori, T. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2485 · Cited by 12
“Furthermore, antipsychotics that act as dopamine receptor antagonists are used as an augmentation strategy for SSRI in SSRIresistant patients with OCD (Bloch et al., 2006; Arumugham and Reddy, 2013).”
Danovich, L., Weinreb, O., Youdim, M. B. H., & Silver, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000106 · Cited by 11
Obsessive-Compulsive Disorder: An Update for the Clinician
Koran, L. M. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.3.foc299 · Cited by 13
Lee, J., Kim, B., Kim, E., Howes, O. D., Cho, K. I. K., Yoon, Y. B., & Kwon, J. S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2642 · Cited by 11
“Thus, it can be also suggested that nonserotonergic treatments might be a better option than pharmacotherapy in treating EOCD patients, which is consistent with prior studies showing that OCD patients with comorbid tic disorder, whose onset is likely to be adolescence, respond better to dopaminergic pharmacotherapy su…”
BackgroundResultEffectiveness of Electroconvulsive Therapy (ECT) in Parkinsonian Symptoms: A Case Series.
Grover, S., Somani, A., Sahni, N., Mehta, S., Choudhary, S., Chakravarty, R. K., & Rabha, A. M. (2018) · Europe PMC (PubMed Central) · Cited by 11
Effects of Antipsychotic Treatment on Obsessive-Compulsive Symptoms
Schirmbeck, F. N., & Zink, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-12952-5_10 · Cited by 12
Tükel, R., Özata, B., Öztürk, N., Ertekin, B. A., Ertekin, E., & Direskeneli, G. S. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.07.037 · Cited by 12
“Moreover, the results of preclinical and clinical studies provide growing evidence suggesting an increased dopaminergic neurotransmission in OCD [2,4,5].”
BackgroundSuccessful Aripiprazole Augmentation in a Child With Drug-Resistant Obsessive-Compulsive Disorder
Öztürk, M., & Coşkun, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bfe068 · Cited by 11
Brakoulias, V., & Tsalamanios, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1250886 · Cited by 13
Co-Occurring Anxiety in Youth with Tic Disorders: A Review
Sapozhnikov, Y., & Vermilion, J. A. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0091 · Cited by 10
Naguy, A., Alamiri, B., AlKhadhari, S., & Francis, K. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0083 · Cited by 10
“Agents that are commonly employed are clomipramine (CMI) (Stein et al. 2012) and the atypical antipsychotics (Bloch et al. 2006; Stein et al. 2012), but a multitude of other drugs have also been tried, such as stimulants, gabapentin, sumatriptan, pindolol, inositol, opiates, St. John’s wort, N…”
Biological treatments for obsessive-compulsive and related disorders
Borue, X., Sharma, M., & Hudak, R. (2015) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2015.03.003 · Cited by 12
Brožka, H., Radostová, D., Pištíková, A., Valeš, K., & Stuchlík, A. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.042 · Cited by 10
Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders
Nadai, A. S. D., Storch, E. A., Mcguire, J. F., Lewin, A. B., & Murphy, T. K. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s6616 · Cited by 10
Neurobiology Confirms Psychopathology
Zink, M., Englisch, S., & Dreßing, H. R. (2008) · Psychopathology · doi:10.1159/000141922 · Cited by 11
Berlin, H. A., Hamilton, H., & Hollander, E. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20045 · Cited by 12
Pharmacotherapy for Tourette Syndrome
Jurgen, B., & Greenberg, E. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.08.008 · Cited by 10
Le trouble obsessionnel compulsif
Santos, J. F. A. D., & Mallet, L. (2013) · médecine/sciences · doi:10.1051/medsci/20132912014 · Cited by 10
“L’addition d’un antagoniste dopaminergique, comme la risperidone, peut améliorer les symptômes, surtout s’il existe des tics associés [29, 30].”
BackgroundCooray, S. E., Tassé, M. J., Barnhill, J., & Bhaumik, S. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_22 · Cited by 11
Investıgation of vitamin D levels in obsessive-compulsive disorder
Soyak, H. M., & Karakükçü, Ç. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_26_22 · Cited by 9
Obsessive-Compulsive Disorder with Schizotypal Personality Disorder (Schizotypal OCD)
Poyurovsky, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-12952-5_5 · Cited by 10
Wolmarans, D. W., Stein, D. J., & Harvey, B. H. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170523125256 · Cited by 11
Mosley, P. E., Velakoulis, D., Farrand, S., Marsh, R., Mohan, A., Castle, D. J., & Sachdev, P. S. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211031482 · Cited by 9
“, 2001) even after augmented therapy (Bloch et al., 2006).”
Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas, E., Karaiskos, D., Ilias, Ι., Liappas, I., & Paparrigopoulos, T. J. (2014) · PubMed · Cited by 9
Dold, M., Bartova, L., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., & Kasper, S. F. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.033 · Cited by 9
Pediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges
Younus, S., Havel, L. K., Stiede, J. T., Rast, C. E., Saxena, K., Goodman, W. K., & Storch, E. A. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00639-5 · Cited by 9
“Augmenting SRIs with low-dose antipsychotic medication may be an effective strategy, supported by evidence for adults with treatment-resistant OCD [53–55].”
Pélissolo, A., Moukheiber, A., & Mallet, L. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.08.020 · Cited by 9
“Neurobiological models of OCD are linked to dysfunctional dopaminergic systems (Bloch et al., 2006) which is not the case in most anxiety disorder models.”
BackgroundDelorme, R., Betancur, C., Chaste, P., Kernéis, S., Stopin, A., Mouren, M., Collet, C., Bourgeron, T., Leboyer, M., & Launay, J. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31016 · Cited by 9
“, 1983], and the therapeutic benefits obtained by co-administration of dopaminergic blockers [Bloch et al., 2006].”
BackgroundInfluentialLeckman, J. F., & Bloch, M. H. (2015) · Wiley eBooks · doi:10.1002/9781118381953.ch56 · Cited by 10
Self-citationRoessner, V., & Rothenberger, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_26 · Cited by 8
The Serotonergic System in Obsessive-Compulsive Disorder
van Dijk, A., Klompmakers, A. A., & Denys, D. A. J. P. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70100-4 · Cited by 9
The Potential Use of Neuroimaging Biomarkers in the Treatment of Obsessive-Compulsive Disorder
Fullana, M. A., & Simpson, H. B. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0087-4 · Cited by 8
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research
Koran, L. M., & Aboujaoude, E. N. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170526120916 · Cited by 10
Eosinophilic Meningoencephalitis: Psychiatric Presentation and Treatment
Hong, D. S., Bernstein, M., Smith, C. K., Gans, H. A., & Shaw, R. J. (2008) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.38.3.e · Cited by 8
“There have been case reports of obsessivecompulsive behavior induced by atypical antipsychotics in the literature [41-43], although data also exists to support the use of atypicals in treating obsessivecompulsive symptoms [44, 45].”
ResultSkarphéðinsson, G., & Ivarsson, T. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0047-0 · Cited by 8
Otsuka, T., Togo, T., Sugiyama, N., Uehara, K., Yoshimi, A., Karashima, A., Shioya, H., & Hirayasu, Y. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.014 · Cited by 8
“Recent studies have shown that second-generation antipsychotics (SGAs) may be useful in augmenting the effectiveness of SSRIs in refractory OCD patients (D'Amico et al., 2003; Bloch et al., 2006; Eddy et al., 2004; Li et al., 2005).”
BackgroundDose-related exacerbation of obsessive–compulsive symptoms with quetiapine treatment
Chen, C., Chiu, C.-C., & Huang, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.024 · Cited by 8
Effect of Aripiprazole Augmentation for Treatment-Resistant Somatoform Disorder: A Case Series
Nagoshi, Y., Tominaga, T., & Fukui, K. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000063 · Cited by 9
Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report
Scala, M., Biondi, L., Serretti, A., & Fabbri, C. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000561 · Cited by 7
Ghasemi, F., Shalbaf, A., & Esteki, A. (2025) · IEEE Access · doi:10.1109/access.2025.3558845 · Cited by 8
“Bloch et al. attempted to find predictors of response to cognitive behavioral therapy (CBT) for individuals with OCD [14].”
Batmaz, S., Yıldız, M., & Songur, E. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1041157 · Cited by 7
Diniz, J. B., Costa, D. L. C., Cassab, R. C., Pereira, C. A., Miguel, E. C., & Shavitt, R. G. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113512042 · Cited by 8
Szechtman, H., Shivji, S., & Woody, E. Z. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_118 · Cited by 9
Angelucci, F., Ricci, V., Martinotti, G., Caltagirone, C., & Bria, P. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.014 · Cited by 8
Behavioral disorders in multiple sclerosis: a comprehensive review
Jellinger, K. A. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02816-9 · Cited by 6
“In treatment resistant OCD, antipsychotic agents have shown efficacy, including haloperidol, risperidone, olanzapine and quetiap-ine (Bloch et al. 2006 ).”
Szechtman, H., Shivji, S., & Woody, E. Z. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_118-1 · Cited by 6
Zwangs- und verwandte Störungen im Licht der neuen DSM-5 Kriterien
Hartmann, A. S., & Wilhelm, S. (2013) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747/a000153 · Cited by 6
Moving beyond first-line treatment options for OCD
Paxos, C. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.10.300 · Cited by 7
Obsessive-Compulsive Disorder in Childhood
rio, M. C. D. R. A., de Alvarenga, P. G., de Mathis, M. A. S., & Leckman, J. F. (2008) · KARGER eBooks · doi:10.1159/000118518 · Cited by 8
Self-citationHegde, A., Kalyani, B. G., Arumugham, S. S., Narayanaswamy, J. C., Math, S. B., & Reddy, Y. C. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000515 · Cited by 6
Treatment of Psychiatric Comorbidities in Tourette Syndromes
Cardona, F., & Rizzo, R. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0025 · Cited by 6
Assarian, F., Ghoreishi, F. S., Borna, M., & Razzaghof, M. (2016) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.41418 · Cited by 7
“Therefore, it is necessary to investigate more effective treatment modalities (2, 7-10) recently used by clinicians (12).”
BackgroundResultInfluentialBloch, M. H., Artukoglu, B. B., Lennington, J. B., Szuhay, G., & Lombroso, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00039-4 · Cited by 7
Self-citationÇocukluk Çağı Başlangıçlı Obsesif Kompulsif Bozukluk
Karaman, D., Durukan, İ., & Erdem, M. (2014) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.133410 · Cited by 17
Obsessive–Compulsive Disorders
Wewetzer, C., & Walitza, S. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_21 · Cited by 7
Avances en el tratamiento farmacológico del trastorno obsesivo-compulsivo.
Vega‐Dienstmaier, J. M. (2017) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v79i4.2978 · Cited by 7
Wewetzer, C., & Walitza, S. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_27 · Cited by 6
Swisher, V. S., Leman, T. Y., Piacentini, J. C., & Ricketts, E. J. (2023) · Current Developmental Disorders Reports · doi:10.1007/s40474-023-00284-6 · Cited by 5
“Among adults with treatment-refractory OCD, augmentation with aripiprazole, risperidone, and haloperidol is efficacious [77, 78], and comorbid tics are associated with a more positive response to augmentation with neuroleptics compared to OCD without comorbid tics [77].”
The Developmental Neurobiology of Repetitive Behavior
Kim, S., Lewis, M. H., & Veenstra-VanderWeele, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397267-5.00039-x · Cited by 7
Pediatric obsessive–compulsive disorder: management priorities in primary care
Gilbert, A. R., & Maalouf, F. T. (2008) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32830f93d9 · Cited by 6
Grassi, G. (2013) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.s10-002 · Cited by 5
“However, only a third of resistant-patients respond to this treatment [5].”
BackgroundPrazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD
Feenstra, M. G. P., Klompmakers, A. A., Figee, M., Fluitman, S. B. A. H. A., Vulink, N. C. C., Westenberg, H. G. M., & Denys, D. A. J. P. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.008 · Cited by 5
Gök, Ş., Demet, M. M., & Öztürk, Z. (2017) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2017.08.003 · Cited by 5
Anxiety Disorders in Children and Adolescents: Assessment and Treatment
Settipani, C. A., Brodman, D. M., Peterman, J. S., Read, K. L., Hoff, A. L., Swan, A. J., & Kendall, P. C. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch49 · Cited by 8
Die Zwangsstörung - Krankheitsbild, Diagnostik und Therapie
Zaudig, M. (2011) · Zeitschrift für psychosomatische Medizin und Psychotherapie · doi:10.13109/zptm.2011.57.1.3 · Cited by 14
Current pharmacological and non pharmacological treatments for obsessivecompulsive disorder
Marazziti, D., Picchetti, M., Baroni, S., Ceresoli, D., Consoli, G., & Dell’Osso, M. C. (2012) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 9
Transtorno Obsessivo Compulsivo
Rosario-Campos, M. C. D., & Mercadante, M. T. (2020) · International Journal of Psychological Research and Reviews · doi:10.28933/ijprr-2020-08-1005 · Cited by 5
Pharmacological Treatment of Internet Addiction
Camardese, G., Leone, B., Walstra, C., Janiri, L., & Guglielmo, R. (2017) · Studies in neuroscience, psychology and behavioral economics · doi:10.1007/978-3-319-46276-9_14 · Cited by 5
Behavior Therapy and Cognitive‐Behavioral Therapy
Craighead, W. E., Craighead, L. W., Ritschel, L. A., & Zagoloff, A. D. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop208012 · Cited by 7
Antipsychotics in anxiety disorders: An oxymoron or a reflection of non-adequate nomenclature?
Zohar, J., & Allgulander, C. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.02.003 · Cited by 5
Baweja, R. K., Waschbusch, D. A., Rajalakshmi, A. K., Petrovic-Dovat, L., & Waxmonsky, J. G. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2025.0049 · Cited by 6
Ghobadian, A., Mokhtari, S., Shariati, B., Kamalzadeh, L., Shati, M., Ardebili, M. E., Yarahmadi, M., & Shalbafan, M. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00610-5 · Cited by 5
“The efficacy of dopamine antagonists in the treatment of OCD, which has been shown in previous studies, supports this hypothesis as well[39, 40].”
ResultObsessive-Compulsive Symptoms in Schizophrenia: Neurophysiological and Neuroimaging Findings
Rao, N.-R. P., & Venkatasubramanian, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-12952-5_9 · Cited by 6
Cortese, S., Besag, F., Clark, B., Hollis, C. P., Kilgariff, J., Moreno, C., Nicholls, D., Wilkinson, P. O., Woodbury‐Smith, M., & Sharma, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140005 · Cited by 5
“Approximately one-third of treatment-resistant cases of OCD will show an additional response to adding low dose antipsychotics to the SSRI (Bloch et al., 2006).”
Başgül, Ş. S. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20121203034039 · Cited by 4
Stein, D. J. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.951 · Cited by 4
Danovich, L., Weinreb, O., Youdim, M. B. H., & Silver, H. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2530-y · Cited by 4
Sepehrmanesh, Z., Adel, M., Ahmadvand, A., & Sehat, M. (2020) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.100918 · Cited by 7
“The response to treatment is also higher than the mean treatment response to antipsychotic augmentation to the main treatment (8).”
Background
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.